The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | CAR-T in multiple myeloma: cilta-cel & ide-cel
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT
